EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans

Jordan Savold, Michele Cole, Roland J Thorpe

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2023-07 · 9 (3)

DOI: 10.1002/trc2.12402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 04.07.2023. Verfasst von Jordan Savold und 2 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Black Americans are disproportionately burdened by Alzheimer's disease (AD) relative to other racial groups in the United States and continue to be underrepresented in AD clinical trials. This review explores the primary barriers for participation in clinical trials among Black Americans and provides literature‐based recommendations to improve the inclusion of Black Americans in AD clinical trials.

Methods

We searched electronic databases and gray literature for articles published in the United States through January 1, 2023, ultimately identifying 26 key articles for inclusion.

Results

Barriers to participation in clinical trials for Black Americans are rooted in social determinants of health, including access to quality education and information, access to health care, economic stability, built environment, and community context. Best practices to improve the inclusion of Black Americans in clinical trials require pharmaceutical companies to adopt a multifaceted approach, investing in innovative strategies for site selection, development of local partnerships, outreach, and education.

Discussion

While multisectoral action must occur to effectively address the disproportionate burden of AD on Black Americans, the pharmaceutical industry has an important part to play in this space due to their central role in product development and clinical trials.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseBlack Americansbarriersbest practicesclinical trialscommunity engagementhealth equitymarket accesspharmaceutical interventionracial disparitiessocial determinants of healthtreatment

Autor:innen und Institutionen

  • Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA.
  • Global Market Access, Neuroscience Therapeutic Area Johnson & Johnson Raritan New Jersey USA.
  • Johns Hopkins Alzheimer's Disease Resource Center for Minority Aging Research Baltimore Maryland USA.
  • Johns Hopkins Center for Health Disparities Solutions Baltimore Maryland USA.

Förderung

  • NIA NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Savold, J., Cole, M., & Thorpe, R. J. (2023). Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 9(3). https://doi.org/10.1002/trc2.12402

Vancouver

Savold J, Cole M, Thorpe RJ. Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2023;9(3). doi:10.1002/trc2.12402

BibTeX
@article{Savold2023,
  author = {Savold, Jordan and Cole, Michele and Thorpe, Roland J},
  title = {Barriers and solutions to Alzheimer's disease clinical trial participation for Black Americans},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2023},
  volume = {9},
  number = {3},
  doi = {10.1002/trc2.12402}
}
Kostenlos starten →